Mark J. Taylor

18.5k total citations · 1 hit paper
181 papers, 7.9k citations indexed

About

Mark J. Taylor is a scholar working on Infectious Diseases, Insect Science and Ecology. According to data from OpenAlex, Mark J. Taylor has authored 181 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Infectious Diseases, 82 papers in Insect Science and 51 papers in Ecology. Recurrent topics in Mark J. Taylor's work include Parasitic Diseases Research and Treatment (140 papers), Insect symbiosis and bacterial influences (80 papers) and Parasite Biology and Host Interactions (51 papers). Mark J. Taylor is often cited by papers focused on Parasitic Diseases Research and Treatment (140 papers), Insect symbiosis and bacterial influences (80 papers) and Parasite Biology and Host Interactions (51 papers). Mark J. Taylor collaborates with scholars based in United Kingdom, Germany and United States. Mark J. Taylor's co-authors include Achim Hoerauf, Moses J. Bockarie, Helen F. McGarry, H. F. Cross, Claudio Bandi, Louise Ford, Joseph D. Turner, A. E. Bianco, Kelly L. Johnston and Sabine Mand and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark J. Taylor

177 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lymphatic filariasis and onchocerciasis

2010 463 citations Mark J. Taylor, Achim Hoerauf et al. profile →

Peers

Countries citing papers authored by Mark J. Taylor

Since Specialization

Citations

This map shows the geographic impact of Mark J. Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Taylor more than expected).

Fields of papers citing papers by Mark J. Taylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Taylor. The network helps show where Mark J. Taylor may publish in the future.

Co-authorship network of co-authors of Mark J. Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Taylor. A scholar is included among the top collaborators of Mark J. Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Taylor. Mark J. Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ongoing transmission of onchocerciasis in the Pru District of Ghana after two decades of mass drug administration with ivermectin and comparative identification of members of the Simulium damnosum complex using cytological and morphological techniques 2024 ·Parasites & Vectors ·(unknown), (unknown), Samuel Armoo, Daniel A. Boakye, Mark J. Taylor, Mike Y. Osei‐Atweneboana	0
2	A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti‐Wolbachia Candidate Macrofilaricide 2024 ·Clinical Pharmacology in Drug Development ·(unknown), Marcin Bula, (unknown), Richard J. Fitzgerald, (unknown), (unknown), Tomoyuki Moriyama, Raku Shinkyo, Lauren Walker, Duolao Wang, Fabian Gusovsky, (unknown), Joseph D. Turner, W. David Hong, Paul M. O’Neill, Mark J. Taylor, Stephen A. Ward	1
3	The national distribution of lymphatic filariasis cases in Malawi using patient mapping and geostatistical modelling 2024 ·PLoS neglected tropical diseases ·(unknown), John Chiphwanya, (unknown), (unknown), (unknown), (unknown), Joseph D. Turner, Emanuele Giorgi, (unknown), Sarah Martindale, Mark J. Taylor, Jonathan M. Read, Louise A. Kelly‐Hope	2
4	Targeting a microbiota Wolbachian aminoacyl-tRNA synthetase to block its pathogenic host 2024 ·Science Advances ·Guillaume Hoffmann, Maria Lukarska, Rachel H. Clare, (unknown), Kelly L. Johnston, Louise Ford, Joseph D. Turner, Stephen A. Ward, Mark J. Taylor, Malene Ringkjøbing Jensen, Andrés Palencia	1
5	Dirofilariasis mouse models for heartworm preclinical research 2023 ·Frontiers in Microbiology ·(unknown), (unknown), (unknown), Andrew Steven, (unknown), (unknown), Abdelmoneim Mansour, Edward J. Campbell, Craig M. Wilson, Fabian Gusovsky, Stephen A. Ward, (unknown), Paul M. O’Neill, (unknown), (unknown), John W. McCall, Mark J. Taylor, Joseph D. Turner	7
6	Mental health conditions in people affected by filarial lymphoedema in Malawi: prevalence, associated risk factors and the impact of an enhanced self-care intervention 2023 ·International Health ·(unknown), John Chiphwanya, (unknown), (unknown), Joseph D. Turner, Mark J. Taylor, Jonathan M. Read, Louise A. Kelly‐Hope	8
7	Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor–mediated lymphangiogenesis 2021 ·Journal of Clinical Investigation ·(unknown), Stephen D. Cross, (unknown), Nicolas Pionnier, John Archer, Andrew Steven, Stefan Schulte‐Merker, Matthias Mack, Young‐Kwon Hong, Mark J. Taylor, Joseph D. Turner	26
8	Development of Pyrazolopyrimidine Anti-Wolbachia Agents for the Treatment of Filariasis 2021 ·ACS Medicinal Chemistry Letters ·(unknown), Neil G. Berry, Gemma L. Nixon, Suet C. Leung, Peter J. H. Webborn, Mark C. Wenlock, Stefan Kavanagh, Andrew Cassidy, Rachel H. Clare, Darren A. N. Cook, Kelly L. Johnston, Louise Ford, Stephen A. Ward, Mark J. Taylor, W. David Hong, Paul M. O’Neill	6
9	Eosinophil-Mediated Immune Control of Adult Filarial Nematode Infection Can Proceed in the Absence of IL-4 Receptor Signaling 2020 ·The Journal of Immunology ·Nicolas Pionnier, Hanna Sjoberg, (unknown), (unknown), Alice Halliday, John Archer, Andrew Steven, Mark J. Taylor, Joseph D. Turner	12
10	In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis 2020 ·PLoS neglected tropical diseases ·Alexandra Ehrens, Christopher S. Lunde, Robert T. Jacobs, (unknown), Marianne Koschel, Stefan J. Frohberger, (unknown), (unknown), Joseph D. Turner, Stephen A. Ward, Mark J. Taylor, Yvonne R. Freund, Rianna Stefanakis, Eric E. Easom, Xianfeng Li, Jacob J. Plattner, Achim Hoerauf, Marc P. Hübner	12
11	In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae 2019 ·PLoS neglected tropical diseases ·Marc P. Hübner, Marianne Koschel, (unknown), (unknown), Stefan J. Frohberger, Alexandra Ehrens, (unknown), (unknown), Thomas W von Geldern, Kennan C. Marsh, Joseph D. Turner, Mark J. Taylor, Stephen A. Ward, Kenneth Pfarr, Dale J. Kempf, Achim Hoerauf	23
12	Interleukin-4 activated macrophages mediate immunity to filarial helminth infection by sustaining CCR3-dependent eosinophilia 2018 ·PLoS Pathogens ·Joseph D. Turner, Nicolas Pionnier, (unknown), Hanna Sjoberg, Stephen D. Cross, Alice Halliday, Ana F. Guimaraes, Darren A. N. Cook, Andrew Steven, Nico van Rooijen, Judith E. Allen, Stephen J. Jenkins, Mark J. Taylor	35
13	ST2 Deficiency Does Not Impair Type 2 Immune Responses during Chronic Filarial Infection but Leads to an Increased Microfilaremia Due to an Impaired Splenic Microfilarial Clearance 2014 ·PLoS ONE ·Jesuthas Ajendra, Sabine Specht, (unknown), Fabian Gondorf, David Schmidt, Katrin Gentil, W. H. Hoffmann, Mark J. Taylor, Achim Hoerauf, Marc P. Hübner	27
14	Whole-Genome Sequencing of Trypanosoma brucei Reveals Introgression between Subspecies That Is Associated with Virulence 2013 ·mBio ·Ian Goodhead, Paul Capewell, J. Wendi Bailey, (unknown), Michaël La Chance, Suzanne Kay, Sarah Forrester, Annette MacLeod, Mark J. Taylor, Harry Noyes, Neil Hall	42
15	Schistosomiasis and water-related practices in school girls in rural KwaZulu-Natal, South Africa : original research 2010 ·(unknown), Jane Kvalsvig, Svein Gunnar Gundersen, Mark J. Taylor, Eyrun Floerecke Kjetland	1
16	Current practices in the management of lymphatic filariasis 2009 ·Expert Review of Anti-infective Therapy ·Moses J. Bockarie, Mark J. Taylor, John O. Gyapong	70
17	Innate Immune Responses to Endosymbiotic Wolbachia Bacteria in Brugia malayi and Onchocerca volvulus Are Dependent on TLR2, TLR6, MyD88, and Mal, but Not TLR4, TRIF, or TRAM 2007 ·The Journal of Immunology ·Amy G. Hise, (unknown), Illona Gillette‐Ferguson, Eun Cho, Helen F. McGarry, Mark J. Taylor, Douglas T. Golenbock, Katherine A. Fitzgerald, James W. Kazura, Eric Pearlman	86
18	Wolbachia.Bacterial Endosymbionts of Filarial Nematodes 2005 ·Advances in Parasitology ·Mark J. Taylor, Claudio Bandi, Achim Hoerauf	303
19	The Role of Endosymbiotic Wolbachia Bacteria in the Pathogenesis of River Blindness 2002 ·Science ·(unknown), (unknown), Laurie R. Hall, Achim Hoerauf, Norbert W. Brattig, Lars Volkmann, Mark J. Taylor, Louise Ford, Amy G. Hise, Jonathan H. Lass, Eugenia Diaconu, Eric Pearlman	259
20	Wolbachia Endosymbiotic Bacteria of Filarial Nematodes. A New Insight into Disease Pathogenesis and Control 2002 ·Archives of Medical Research ·Mark J. Taylor	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact